Colony stimulating factors (including erythropoietin, granulocyte colony stimulating factor and analogues) for stroke

Granulocyte Colony-Stimulating Factor Enhances Arteriogenesis and Ameliorates Cerebral Damage in a Mouse Model of Ischemic Stroke

“…11,15 We observed an arteriogenic effect of G-CSF at the dose of 10 g/kg/day for 5 days. Recent clinical studies used G-CSF at 1 to 10 g/kg for 5 days in patients with stroke and demonstrated its safety.…”

“…Recent clinical studies used G-CSF at 1 to 10 g/kg for 5 days in patients with stroke and demonstrated its safety. 11 Another trial is ongoing to test the safety at higher doses (up to 100 g/kg/day or total of 180 g/kg over 3 days). 15 One particular safety concern might be the possibility that increased blood neutrophils aggregate within microvasculature and impair tissue circulation.…”

Granulocyte Colony-Stimulating Factor Enhances Arteriogenesis and Ameliorates Cerebral Damage in a Mouse Model of Ischemic Stroke

“…11,15 We observed an arteriogenic effect of G-CSF at the dose of 10 g/kg/day for 5 days. Recent clinical studies used G-CSF at 1 to 10 g/kg for 5 days in patients with stroke and demonstrated its safety.…”

“…Recent clinical studies used G-CSF at 1 to 10 g/kg for 5 days in patients with stroke and demonstrated its safety. 11 Another trial is ongoing to test the safety at higher doses (up to 100 g/kg/day or total of 180 g/kg over 3 days). 15 One particular safety concern might be the possibility that increased blood neutrophils aggregate within microvasculature and impair tissue circulation.…”

Granulocyte-Colony Stimulating Factor for Mobilizing Bone Marrow Stem Cells in Subacute Stroke

“…Although G-CSF transiently increases total white cell count, therefore potentially leading to vascular complications, there is currently no evidence to suggest that G-CSF causes thromboembolic events or aggravates stroke symptoms. 19 All 4 of the trials were too small individually to assess the effect of G-CSF on functional outcome; when data from the 4 trials are aggregated, no safety concern is obvious with G-CSF (odds ratio: 1.11 [95% CI: 0.38 -3.25]; Figure 4). In light of the above evidence and a recent negative trial assessing administration of erythropoietin (another colonystimulating factor 20 ) within 6 hours of ischemic stroke, 21 further phase II/III trials are required evaluating the safety and efficacy of G-CSF.…”

Bronchogenic adenocarcinoma presenting as a synchronous solitary lytic skull lesion with ischaemic stroke – case report and literature review

“…Colony-stimulating factors for example, erythropoietin and granulocyte CSF are considered to be beneficial in stroke management 19. Other drugs for example, all-trans retinoic acid and corticosteroids are reported to have thrombogenic potential20 which can potentially lead to stroke.…”

Granulocyte Colony-Stimulating Factor Enhances Arteriogenesis and Ameliorates Cerebral Damage in a Mouse Model of Ischemic Stroke

“…11,15 We observed an arteriogenic effect of G-CSF at the dose of 10 g/kg/day for 5 days. Recent clinical studies used G-CSF at 1 to 10 g/kg for 5 days in patients with stroke and demonstrated its safety.…”

“…Recent clinical studies used G-CSF at 1 to 10 g/kg for 5 days in patients with stroke and demonstrated its safety. 11 Another trial is ongoing to test the safety at higher doses (up to 100 g/kg/day or total of 180 g/kg over 3 days). 15 One particular safety concern might be the possibility that increased blood neutrophils aggregate within microvasculature and impair tissue circulation.…”

Granulocyte-Colony Stimulating Factor for Mobilizing Bone Marrow Stem Cells in Subacute Stroke

“…Although G-CSF transiently increases total white cell count, therefore potentially leading to vascular complications, there is currently no evidence to suggest that G-CSF causes thromboembolic events or aggravates stroke symptoms. 19 All 4 of the trials were too small individually to assess the effect of G-CSF on functional outcome; when data from the 4 trials are aggregated, no safety concern is obvious with G-CSF (odds ratio: 1.11 [95% CI: 0.38 -3.25]; Figure 4). In light of the above evidence and a recent negative trial assessing administration of erythropoietin (another colonystimulating factor 20 ) within 6 hours of ischemic stroke, 21 further phase II/III trials are required evaluating the safety and efficacy of G-CSF.…”

Bronchogenic adenocarcinoma presenting as a synchronous solitary lytic skull lesion with ischaemic stroke – case report and literature review

“…Colony-stimulating factors for example, erythropoietin and granulocyte CSF are considered to be beneficial in stroke management 19. Other drugs for example, all-trans retinoic acid and corticosteroids are reported to have thrombogenic potential20 which can potentially lead to stroke.…”

Granulocyte Colony-Stimulating Factor Enhances Arteriogenesis and Ameliorates Cerebral Damage in a Mouse Model of Ischemic Stroke

“…11,15 We observed an arteriogenic effect of G-CSF at the dose of 10 g/kg/day for 5 days. Recent clinical studies used G-CSF at 1 to 10 g/kg for 5 days in patients with stroke and demonstrated its safety.…”

“…Recent clinical studies used G-CSF at 1 to 10 g/kg for 5 days in patients with stroke and demonstrated its safety. 11 Another trial is ongoing to test the safety at higher doses (up to 100 g/kg/day or total of 180 g/kg over 3 days). 15 One particular safety concern might be the possibility that increased blood neutrophils aggregate within microvasculature and impair tissue circulation.…”

Granulocyte-Colony Stimulating Factor for Mobilizing Bone Marrow Stem Cells in Subacute Stroke

“…Although G-CSF transiently increases total white cell count, therefore potentially leading to vascular complications, there is currently no evidence to suggest that G-CSF causes thromboembolic events or aggravates stroke symptoms. 19 All 4 of the trials were too small individually to assess the effect of G-CSF on functional outcome; when data from the 4 trials are aggregated, no safety concern is obvious with G-CSF (odds ratio: 1.11 [95% CI: 0.38 -3.25]; Figure 4). In light of the above evidence and a recent negative trial assessing administration of erythropoietin (another colonystimulating factor 20 ) within 6 hours of ischemic stroke, 21 further phase II/III trials are required evaluating the safety and efficacy of G-CSF.…”

Bronchogenic adenocarcinoma presenting as a synchronous solitary lytic skull lesion with ischaemic stroke – case report and literature review

“…Colony-stimulating factors for example, erythropoietin and granulocyte CSF are considered to be beneficial in stroke management 19. Other drugs for example, all-trans retinoic acid and corticosteroids are reported to have thrombogenic potential20 which can potentially lead to stroke.…”